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Background: Biomarkers that predict the rate of HIV disease
rogression in HIV-infected children might assist in clinical deci-
ions of when to start ARV among children with mild to moderate
mmune suppression.
Methods: This is a substudy of the PREDICT study, a random-
zed trial of immediate versus deferred antiretroviral initiation in
hildren aged 1-12 years in Thailand and Cambodia. HIV-infected
hildren with CD4 15-24% had CD4 monitoring every 12 weeks and
tarted ART when CD4<15%. Long term non progressors (LTNP)
ere deﬁned as age>8 years anytime during the study with
D4>15%, slow progressors were <8 years with CD4>15% at the
tudy end, and routine progressors had CD4 decline to <15% before
ge 8 years. BaselineHIV RNA, soluble CD14 (sCD14) and C-reactive
rotein (CRP) were measured and multinomial logistic regression
as performed to discern relative risk (RR) ratios of disease pro-
ression for each biomarker with LTNP as a reference group.
Results: There were 147 HIV-infected children with mean age
f 6.5 years, %CD4 of 20.6, plasma HIV RNA of 4.6 log10 copies/ml.
here were 85,25 and,37 children in LTNP, slow and routine pro-
ressor groups, respectively. Inmultivariatemodels, the RR (95%CI)
f being a slow progressor for children with baseline viral load ≥
log10 copies/ml was 6.0 (1.9-18.6; p =0.002) after adjusting for
CD14 and CRP. The RR (95% CI) of being a routine progressor for
hildren with baseline viral load ≥ 5 log10 copies/ml was 25.2 (8.1
77.7; p <0.0001) and 5.1 (1.6 – 16.0; p =0.006) in those with CRP
3mg/L after adjusting for sCD14. Although mean (SD) sCD14 was
igniﬁcantlyhigher in the routineprogressors versus the LTNP (1.96
0.43) vs 1.66(0.38) million pg/mL; P <0.001), it was not signiﬁcant
n a multivariate model after adjusting for viral load and CRP.fectious Diseases 16S (2012) e158–e316 e193
Conclusion: Baseline HIV RNA ≥ 5 log and CRP ≥ 3mg/L are
independent predictors of faster HIV disease progression rates. HIV
RNA with/without CRP could aid in deciding which children should
start ARV sooner.
http://dx.doi.org/10.1016/j.ijid.2012.05.763
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Background: A human monoclonal antibody, IgG1 b12 (b12)
recognizes a conformational epitope on human immunodeﬁciency
virus type 1 (HIV-1) envelope glycoprotein (Env) gp120 that
overlaps the CD4 binding site. Although b12 is able to broadly
neutralize HIV-1 subtype B, C and D viruses, it poorly neutralizes
most CRF01 AE viruses. In this report, we examined the mecha-
nisms underlying low b12 susceptibility of CRF01 AE viruses, using
recently established CRF01 AE Env (AE-Env)-recombinant viruses.
Methods: AE-Env genes were cloned into the pNL4-3-derived
luciferase reporter proviral construct, pNL-envCT to generate
AE-Env-recombinant viruses. In addition, N-linked glycosylation
mutantswere generated by site-directedmutagenesis. Viral super-
natants were prepared by transfecting 293T cells with the proviral
construct. Then, neutralization susceptibility of the recombinant
viruses to b12 was examined.
Results: We found that two potential N-linked glycosylation
(PNLG) sites, designated as N186 and N197 (amino acid num-
bering is based on HXB2 Env), in the V2 and C2 region of Env
gp120 played an important role in regulating the b12 suscepti-
bility of AE-Env-recombinant viruses. Namely, removal of N186
and/or N197 conferred the b12 susceptibility of 15 resistant AE-
Env-recombinant viruses, whereas the removal of N301, N339,
N386orN392 fromthe remainingb12-resistant viruses fromwhich
N186 and/or N197 had been removed was not sufﬁcient to confer
the b12 susceptibility. Interestingly, the introduction of an aspartic
acid at residue 185 into a resistant virus fromwhichN197 had been
removed, 47CC11-N197Q-G185D, conferred the b12 susceptibility.
In addition, the introduction of D185 into this virus from which
N197 was not removed, 47CC11-G185D, also increased the b12
susceptibility, although the extent of b12 susceptibility was lower
than that of 47CC11-N197Q-G185D. The conservation of D185 in
Subtype B, C and CRF01 AE which obtained from the HIV sequence
